Stocks · News reference
Aberdeen Group plc has notified Bloomsbury Publishing plc that its voting rights in the company have fallen below the 5% threshold.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Beeline Medicines Corporation announced Phase 2 study results for afimetoran, an investigational TLR7/8 inhibitor originally discovered by Bristol Myers Squibb.
Bloomsbury Publishing has announced it will publish 'Dancing Through Life: A Broadway Memoir of Luck & Talent' by Larry Fuller in May 2027.
Bristol Myers Squibb has triggered a clinical development milestone payment to Editas Medicine, as reported in the latter's third-quarter 2026 financial update.
Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.
BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.
Bristol Myers Squibb presented 56-week Phase 3 clinical trial data for Camzyos (mavacamten) in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy at the HCMS Scientific Sessions.